Chronic kidney disease (CKD) affects more than 35 million Americans, and up to 9 in 10 adults with the condition don’t know they have it. Often called a “silent killer,” CKD is typically diagnosed in later stages, when treatment becomes more complex and costly.

In this episode, Fierce Healthcare Senior Writer Anastassia Gliadkovskaya speaks with Carney Taylor, M.D., associate chief medical officer at Interwell Health, about why CKD is ripe for value-based care, how early interventions can improve outcomes, and what it takes to shift kidney care upstream.

To learn more about the topics in this episode: 

• CMMI to cut participation in payment models, estimates $750M in savings
• Humana finds value-based care leads to fewer hospital admissions for kidney patients
• Humana cuts 13-state kidney disease management deal with Interwell Health
• Interwell Health finalizes $2.4B kidney care merger to combine tech, value-based care capabilities